Doxorubicin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Doxorubicin and local guidelines before prescribing.
Mechanism
Anthracycline intercalating DNA and inhibiting topoisomerase II.
Uses
Breast cancer, lymphoma, sarcoma, leukaemia.
Dosing
- Anthracyclines (doxorubicin, epirubicin): Dose-dependent myocyte injury; risk rises steeply above a cumulative doxorubicin dose of about 250 mg/m², with mediastinal radiotherapy, older age, pre-existing heart disease and childhood exposure. Damage may present years later.
Cardiology: Cardiomyopathies
Side effects
Cardiomyopathy (cumulative dose), myelosuppression, alopecia, extravasation necrosis, red urine.
Interactions
Trastuzumab increases cardiotoxicity.
Contraindications and cautions
Cardiomyopathy, severe liver impairment
Monitoring
Echocardiogram, FBC, LFT
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in hepatic impairment
Overdose and reversal
Dexrazoxane for extravasation or cardioprotection
Special advice
Record cumulative dose; baseline echocardiogram; central access.
More from the textbook: uses, cautions and other points
- Anthracyclines (doxorubicin, daunorubicin) - cardiotoxicity (cumulative dose - echocardiogram before and during), red urine.
Haematology: Anatomy Physiology and Pharmacology - ABVD | Hodgkin lymphoma: doxorubicin (cardiotoxic), bleomycin (pulmonary fibrosis) , vinblastine, dacarbazine (nausea); omit bleomycin if interim PET-negative.
Haematology: Myeloma and Lymphoma - Doxorubicin | Cumulative cardiotoxicity (echo); red urine; vesicant.
Oncology: Principles - Early stage: short ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), 2–4 cycles, with or without low-dose involved-site radiotherapy depending on interim PET.
Haematology: Myeloma and Lymphoma - R-CHOP every 21 days for 6 cycles (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone). NICE NG52 recommends polatuzumab vedotin with R-CHP for IPI 2–5. Radiotherapy to bulky sites in selected patients.
Haematology: Myeloma and Lymphoma - R-CHOP / Pola-R-CHP | DLBCL: cyclophosphamide, doxorubicin, vincristine (neuropathy, constipation), prednisolone, rituximab (or polatuzumab replacing vincristine); neutropenia; check echo.
Haematology: Myeloma and Lymphoma - Anthracyclines | Doxorubicin , epirubicin - cardiomyopathy (cumulative dose), red urine, severe tissue damage if they leak (extravasation), hair loss
Oncology: Principles - Burning and swelling at the cannula during doxorubicin | Extravasation
Oncology: Emergencies
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Myeloma and Lymphoma (4 mentions)
- Oncology: Principles (2 mentions)
- Oncology: Emergencies (1 mention)
- Integrated cardiology chapter (1 mention)